PBTrendz

Advertisement

IFTA 2026: India has voted. See the winners.

The ICMR antibiotic resistance report for 2025 shows that several common antibiotics now work on only a small share of the bacteria tested in Indian hospitals. In lab tests, ciprofloxacin stopped just 9 per cent of E. coli samples and about 2 in 100 typhoid samples. The report came out during World AMR Awareness Week, around the same time the health ministry proposed tighter central checks on licences for antibiotics.

Gloved hand holding a petri dish with bacterial colonies in a laboratory

What did the ICMR antibiotic resistance report find?

The report is the Indian Council of Medical Research’s Antimicrobial Resistance Surveillance and Research Network (AMRSN) Annual Report 2025. It tracks how often common medicines still stop the bacteria found in patients at Indian hospitals. Antimicrobial resistance, or AMR, is when bacteria, viruses, fungi or parasites stop responding to medicines, which makes common infections harder or even impossible to treat.

The 2025 edition covers 1,13,008 culture-positive samples collected from 30 large specialised hospitals between January and December 2025. For the first time, it also adds 20,529 samples from 34 secondary-care hospitals, including 12 district hospitals.

The main message is that several everyday antibiotics are losing ground against bacteria behind urinary tract infections (UTIs), pneumonia, bloodstream infections and diarrhoea. The report also points to resistance spreading beyond the big hospitals, and stresses infection prevention alongside correct antibiotic use.

A quick note on the numbers below: when a report says a sample was “susceptible” to a drug, it means the drug stopped that bacteria in a lab test. So “9 per cent susceptible” means the drug worked on only 9 of every 100 samples tested.

Blister strips of colourful tablets and capsules
In lab tests, ciprofloxacin stopped just 9 per cent of E. coli samples from large hospitals.

Which common infections are affected?

E. coli was the most common bacterium in the large hospitals, at 24.4 per cent of samples. It was followed by Klebsiella pneumoniae (16.9 per cent), Pseudomonas aeruginosa (12.2 per cent) and Acinetobacter baumannii (9.5 per cent). Here is what the report found, bug by bug, as reported by news outlets that covered it.

  • E. coli (the most common cause of UTIs): cefotaxime worked on 18.4 per cent of samples, ceftazidime on 24.7 per cent and ciprofloxacin on just 9 per cent. E. coli was also the bacterium found most often in urine samples.
  • Diarrhoea-causing E. coli: ciprofloxacin worked on 0.7 per cent of samples and cefixime on 4.6 per cent.
  • Shigella (diarrhoeal infections): ciprofloxacin worked on 7.5 per cent of Shigella flexneri samples and 8.9 per cent of Shigella sonnei samples.
  • Salmonella Typhi (typhoid): only about 2 in 100 samples responded to ciprofloxacin. Azithromycin and ceftriaxone still worked against typhoid in lab tests.
  • Staphylococcus aureus (skin, wound and blood infections): 56.8 per cent of samples were resistant to methicillin. Some resistance to linezolid was also recorded.
  • Acinetobacter baumannii (hospital infections): over 90 per cent of samples in big hospitals resisted carbapenems, which are “last resort” antibiotics kept for severe infections.
  • Klebsiella in ICUs: samples from intensive care patients showed much higher resistance across major drug classes than samples from outpatients and general wards.

The report says carbapenem resistance is becoming a bigger part of the overall resistance picture. That matters because carbapenems are what doctors turn to when other drugs fail.

Is antibiotic resistance getting worse in India?

The picture is mixed. ICMR itself notes that resistance is not uniform across all bacteria and all medicines. The typhoid result shows this clearly: one drug barely works, while two others still do.

The network’s previous report, for 2024, came out in November 2025 and showed some improvements. Here is how one E. coli number has moved across reports:

  • 2023: ceftazidime worked on 19.2 per cent of E. coli samples
  • 2024: it rose to 27.5 per cent
  • 2025: news coverage of the new report puts it at 24.7 per cent

The 2024 report also showed amikacin working on 72.5 per cent of E. coli samples, up from 68.2 per cent in 2023 but still below 79.2 per cent in 2017. These figures come from different yearly reports and the hospital network has grown, so small changes from one year to the next should be read with care.

The bigger shift in 2025 is where resistance is showing up. By adding district and other secondary-care hospitals, the report finds drug resistance outside the large specialised hospitals too.

Empty beds with blue curtains in a bright hospital ward
In an ICMR study, patients with resistant E. coli stayed in hospital for 23.1 days on average, against 17.8 days for others.

How dangerous is a drug-resistant infection?

A separate ICMR study, published in The Lancet Regional Health – Southeast Asia and reported in early September 2026, put numbers on the harm. Researchers looked at records of nearly 1.6 lakh patients admitted to 20 tertiary-care hospitals between April 2022 and April 2025. Of them, 26,213 had infections caused by four bacteria: E. coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.

In 61.1 per cent of these infections, the bacteria resisted carbapenems. Patients whose infections resisted these drugs died more often in every group:

  • Klebsiella pneumoniae: 31.2 per cent died with resistant infections, against 23.5 per cent with infections that responded to drugs
  • E. coli: 24.4 per cent against 17.3 per cent
  • Acinetobacter baumannii: 37.9 per cent against 32.8 per cent
  • Pseudomonas aeruginosa: 28.9 per cent against 20.2 per cent

Resistance also costs time and money. Patients with resistant E. coli stayed in hospital for 23.1 days on average, against 17.8 days for those whose infection responded to drugs. Antibiotic treatment for resistant E. coli averaged US$420 per patient, about double the US$211 for susceptible cases. With medical costs in India expected to rise 10.1 per cent in 2027, longer hospital stays add up fast for families.

Dr Kamini Walia, a senior ICMR scientist and one of the study’s authors, said AMR is already having a significant impact on patients and healthcare in India.

What is the new rule on antibiotics?

The Union health ministry has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019, news agency ANI reported on 19 November. The draft, Gazette Notification G.S.R. 983(E) dated 6 November, adds “antimicrobials” to the definition of a “new drug” under Rule 2(1)(w)(v).

In plain terms, manufacturers would need permission from the Central Licensing Authority before they get a manufacturing licence for antimicrobial products. The ministry’s concern is that licences have been granted without enough checks, such as bioavailability, bioequivalence and stability studies. It says substandard or ineffective antimicrobials can help resistance develop and spread.

The draft is open for objections and suggestions from stakeholders and the public before the government finalises it. One point is still unclear: the news site transclew, which read the three-page draft, noted that it does not say what happens to medicines already on sale.

Pharmacist checking a medicine bottle in front of pharmacy shelves
A draft rule, G.S.R. 983(E), would require central approval before antimicrobial products get a manufacturing licence.

What do these numbers not tell you?

All the resistance figures come from lab samples of patients sick enough to have a culture test at a hospital. They show what doctors are facing in hospitals. They do not measure how common resistant bacteria are among healthy people in the community.

The report is also a surveillance document, not a treatment guide. Which medicine suits a particular infection depends on the patient and, often, on a culture test. ICMR’s own bulletin says the Prime Minister quoted its earlier AMR report in Mann Ki Baat to warn people against misusing antibiotics.

The report arrived during World AMR Awareness Week, which India is observing from 18 to 24 November 2026. The health ministry opened the national observance on 18 November at Kartavya Bhawan in New Delhi. For another infection India tracks closely, read our explainer on the Global TB Report 2026.

Key numbers

  • 1,13,008: culture-positive samples from 30 large hospitals in the 2025 report
  • 20,529: samples from 34 secondary-care hospitals, added for the first time
  • 9 per cent: E. coli samples on which ciprofloxacin worked
  • About 2 in 100: typhoid samples on which ciprofloxacin worked
  • 56.8 per cent: Staphylococcus aureus samples resistant to methicillin
  • Over 90 per cent: Acinetobacter samples in big hospitals resisting carbapenems
  • 23.1 vs 17.8 days: average hospital stay with resistant vs susceptible E. coli
  • G.S.R. 983(E): the draft that would treat antimicrobials as “new drugs”

What to watch next

  • The final rule: whether the health ministry notifies G.S.R. 983(E) after public comments, and whether it clarifies the position of antibiotics already on the market.
  • District hospital data: 2025 was the first year smaller hospitals were included. Next year’s report will show whether resistance outside large hospitals is growing.
  • Carbapenems: ICMR has flagged rising carbapenem resistance. Watch whether these last-resort drugs lose more ground in the 2026 report.
  • Typhoid and diarrhoea drugs: azithromycin and ceftriaxone still work against typhoid in lab tests. Any fall there would matter, because few other options are left in the lab results.

FAQ

What is the ICMR AMR report 2025?

It is the yearly report of ICMR’s Antimicrobial Resistance Surveillance and Research Network. The 2025 edition studied 1,13,008 samples from 30 large hospitals collected between January and December 2025, plus 20,529 samples from 34 smaller hospitals.

Does ciprofloxacin still work for typhoid?

In the report’s lab tests, only about 2 in 100 typhoid samples responded to ciprofloxacin, while azithromycin and ceftriaxone still worked. These are surveillance figures; treatment for any patient is decided by a doctor.

Why is E. coli a big concern?

E. coli was the most common bacterium in the report and the most common cause of urinary tract infections. Ciprofloxacin worked on only 9 per cent of E. coli samples from large hospitals.

What changes if antimicrobials become “new drugs”?

Under the draft rule, makers would need Central Licensing Authority permission before getting a manufacturing licence for antimicrobial products. The rule is still a draft and open for public comments.